Journal of Renal Nutrition
Volume 13, Issue 4 , Pages 250-258 , October 2003

Uremic malnutrition-inflammation syndrome in chronic renal disease: a pathobiologic entity

  • Fatai O Bamgbola, MD, FMC (Paed), Nigeria

      Affiliations

    • Children’s Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY, USA
    • Corresponding Author InformationAddress reprint requests to Fatai Bamgbola, MD, Montefiore Medical Center, Division of Pediatric Nephrology, 111 E 210th St, Bronx, NY 10467 USA
    • ,
  • Fredrick J Kaskel, MD, PhD

      Affiliations

    • Division of Pediatric Nephrology, Children’s Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY, USA

References 

  1. Kopple JD, Greene T, Chumlea WC, et al.  Relationship between nutritional status and glomerular filtration rate (Results from the MDRD study). Kidney Int. 2000;57:1688–1703
  2. Aguilera A, Codoceo R, Bajo MA, et al.  Helicobacter pylori infection (A new cause of anorexia in peritoneal dialysis patients). Perit Dial Int. 2001;21(Suppl 3):S152–S156
  3. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease before dialysis. Semin Dial. 2003;16:101–105
  4. Lim J, Gasson C, Kaji DM. Urea inhibits NaK2Cl cotransport in human erythrocytes. J Clin Invest. 1995;96:2126–2132
  5. Martin-Malo A, Carracedo J, Ramirez R, et al.  Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol. 2000;11:936–942
  6. Cendroglo M, Jaber BL, Balakrishnan VS, et al.  Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol. 1999;10:93–100
  7. Niwa T. 3-Deoxyglucosone (Metabolism, analysis, biological activity, and clinical implication). J Chromatogr B Biomed Sci Appl. 1999;731:23–26
  8. Guo Z, Hou F, Zhang X, et al.  Advanced glycation end products inhibit production of NO by human endothelial cells through activation of the p38 signal pathway. Zhonghua Yi Xue Za Zhi. 2002;10:1328–1331
  9. Schwedler S, Schinzel R, Vaith P, et al.  Inflammation and advanced glycation end products in uremia (Simple coexistence, potentiation or causal relationship?). Kidney Int. 2001;78(Suppl 78):S32–S326
  10. Aguilera A, Selgas R, Diez JJ, et al.  Anorexia in end stage renal disease (Pathophysiology and treatment). Expert Opin Pharmacother. 2001;2:1825–1838
  11. Mamoun AH, Sodersten P, Anderstam B, et al.  Evidence of splanchnic-brain signaling in inhibition of ingestive behavior by middle molecules. J Am Soc Nephrol. 1999;10:309–314
  12. O’Sullivan AJ, Lawson JA, Chan M, et al.  Body composition and energy metabolism in chronic renal insufficiency. Am J Kidney Dis. 2002;39:369–375
  13. Mitch WE. Insights into the abnormalities of chronic renal disease attributed to malnutrition (Pathophysiology of chronic renal failure and complications). J Am Soc Nephrol. 2002;13(Suppl 1):S22–S27
  14. Odamaki M, Furuya R, Yoneyama T, et al.  Association of serum leptin concentration with weight loss in chronic hemodialysis patients. Am J Kidney Dis. 1999;33:361–368
  15. Astrup A, Toubro S, Dalgaard LT, et al.  Impact of the v/v 55 polymorphism of the uncoupling protein 2 on 24-h energy expenditure and substrate oxidation. Int J Obes Relat Metab Disord. 1999;23:1030–1034
  16. Stevinkel P. The role of inflammation in the anaemia of end stage renal disease. Nephrol Dial Transplant. 2001;16:36–40
  17. Kong QY, Wu X, Li J, et al.  Loss of phospholipid asymmetry in red blood cells contributes to anemia in uremic patients. Adv Perit Dialysis. 2001;17:58–60
  18. Canestrari F, Galli F, Giorgini A, et al.  Erythrocyte redox state in uremic anemia (Effects of hemodialysis and relevance of glutathione metabolism). Acta Hematol. 1994;91:187–193
  19. Besarab A, Amin N, Ahsan M, et al.  Optimization of epoietin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11:530–538
  20. Zima T. Trace elements in end stage renal disease (Clinical implication of trace elements). Blood Purif. 1999;17:187–198
  21. D’Haese PC. Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. 1999;45:1548–1556
  22. Prasad AS, Bao B, Beck FW, et al.  Zinc activates NF-kappa B in HUT-78 cells. J Clin Med. 2001;138:250–256
  23. El Hendy HA, Yousef MI, Abo El-Naga NI. Effect of dietary zinc deficiency on hematological and biochemical parameters and concentrations of zinc, copper, and iron in growing rats. Toxicology. 2001;167:163–170
  24. Jern NA, Van Beber AD, Gorman MA, et al.  The effects of zinc supplementation on serum zinc concentration and protein catabolic rate in hemodialysis patients. J Renal Nutr. 2000;10:148–153
  25. Candan F, Gultekin F, Candan F. Effect of vitamin C and zinc on osmotic fragility and lipid peroxidation in zinc deficient haemodialysis patients. Cell Biochem Funct. 2002;20:95–98
  26. O’Dell BL. Role of zinc in plasma membrane function. J Nutr. 2000;130(Suppl 5S):s1432–s1436
  27. Goral S. Levocarnitine and muscle metabolism in patients with end stage renal disease. J Ren Nutr. 1998;8:118–121
  28. Nikolaos S, George A, Telemachos T, et al.  Effect of L-carnitine supplementation on red cell deformability in hemodialysis patients. Ren Fail. 2000;22:73–80
  29. Matsumato Y, Sato M, Ohashi H, et al.  Effects of L-carnitine on cardiac morbidity in hemodialyzed patients. Am J Nephrol. 2000;20:201–207
  30. Roelfsema V, Clark RG. The growth hormone and insulin-like growth factor axis (Its manipulation for the benefit of growth disorders in renal failure). J Am Soc Nephrol. 2001;12:1297–1306
  31. Morris ST, Jardine AG. The vascular endothelium in chronic renal failure. J Nephrol. 2000;13:96–105
  32. Serradell M, Diaz-Ricart M, Cases A, et al.  Uremic medium disturbs the hemostatic balance of cultured human endothelial cells. Thrombosis Haemostasis. 2001;86:1099–1105
  33. Kaysen GA. The micro-inflammatory state in uremia (Causes and potential consequences). J Am Soc Nephrol. 2001;12:1549–1557
  34. Stenvinkel P, Heimburger O, Tuck CH, et al.  Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int. 1998;53:1336–1342
  35. Schwedler S, Schinzel R, Vaith P, et al.  Inflammation and advanced glycation end products in uremia (Simple co-existence, potentiation or causal relationship?). Kidney Int. 2001;78(Suppl 78):S32–S36
  36. Drueke TB, Khoa TN, Massy ZA, et al.  Role of oxidized low-density lipoprotein in the atherosclerosis of uremia. Kidney Int. 2001;78(Suppl 78):S114–S119
  37. Nakamura T, Saionji K, Hiejiema Y, et al.  Methylene-tetrahdrofolate reductase genotype, vitamin B12 and folate influence plasma homocysteine in hemodialysis patients. Am J Kidney Dis. 2002;39:1032–1039
  38. Mc Gregor DO, Dellow WJ, Lever M, et al.  Dimethyl-glycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int. 2001;59:2267–2272
  39. Mezzano D, Pais EO, Aranda E, et al.  Inflammation, not hyperhomocysteinemia, is related to oxidative and hemostatic and endothelial dysfunction in uremia. Kidney Int. 2001;60:1844–1850
  40. Mendes Ribeiro AC, Brunini TMC, Ellory JC, et al.  Abnormalities in L-arginine transport and nitric oxide biosynthesis in chronic renal and failure. Cardiovasc Res. 2001;49:697–712
  41. Aiello S, Noris M, Remuzzi G. Nitric oxide/L-arginine in uremia. Min Electrol Metabol. 1999;25:384–390
  42. Zhang R, Brennan ML, Fu X, et al.  Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136–2142
  43. Nikpoor B, Turecki G, Fournier C, et al.  A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 2001;142:336–339
  44. Raskova J, Czerwinski DK, Shea SM, et al.  Cellular immunity and lymphocyte populations in developing uremia in the rat. J Exp Pathol. 1986;2:229–245
  45. Libetta C, Rampino T, Dal Canton A. Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. Am J Kidney Dis. 2001;38:286–295
  46. Girndt M, Sester U, Sester M, et al.  Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlate to the uremia-associated immune defect. Kidney Int. 2001;59:1382–1389
  47. Gagnon RF. Delayed-type hypersensitivity skin reaction in the chronically uremic mouse (Influence of severity and duration of uremia on the development of response). Nephron. 1986;43:16–21
  48. Smogorzewski MJ, Massry SG. Defects in B cell function and metabolism in uremia (Role of parathyroid hormone). Kidney Int. 2001;78(Suppl 78):S186–S189
  49. Martin-Malo A, Carracedo J, Ramirez R, et al.  Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol. 2000;11:936–942
  50. Cendroglo M, Jaber BL, Balakrishnan VS, et al.  Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol. 1999;10:93–100
  51. Cohen G, Rudnick M, Walter F, et al.  Glucose modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. J Am Soc Nephrol. 2001;12:1264–1271
  52. Jaber B, Perianayagam MC, Balakrishnan VS, et al.  Mechanisms of neutrophil apoptosis in uremia and relevance of the Fas (APO-1, CD95)/Fas ligand system. J Leucoc Biol. 2001;69:1006–1012
  53. Vanholder R, De Smet R, Waterloos MA, et al.  Mechanisms of uremic inhibition of phagocyte reactive species production (characterization of the role of p-cresol). Kidney Int. 1995;47:510–517
  54. Hirayama A, Noronha-Dutra AA, Gordge MP, et al.  Inhibition of neutrophil superoxide production by uremic concentrations of guanidine compounds. J Am Soc Nephrol. 2000;11:684–689
  55. Deicher R, Exner M, Cohen G, et al.  Neutrophil beta (2)-microglobulin and lactoferrin content in renal failure patients. Am J Kidney Dis. 2000;35:1117–1126
  56. Haag-Weber M, Horl WH. Are granulocyte inhibitory proteins contributing to enhanced susceptibility to infections in uraemia?. Nephrol Dial Transplant. 1996;11(Suppl 2):S98–S100
  57. Stenvinkel P, Wanner C, Metzger T, et al.  Inflammation and to outcome in end-stage renal failure (Does female gender constitute a survival advantage?). Kidney Int. 2002;62:1791–1798
  58. Kimmel PL, Phillips TM, Simmens SJ, et al.  Immunologic function and survival in hemodialysis patients. Kidney Int. 1998;54:236–244
  59. Memoli B, Postiglione L, Cianciaruso B, et al.  Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int. 2002;58:417–424
  60. Girndt M, Kaul H, Sester U, et al.  Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int. 2002;62:945–955
  61. Stenvinkel P, Heimburger O, Jogestrand T, et al.  Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients (Association with Chlamydia pneumoniae seropositivity). Am J Kidney Dis. 2002;39:274–282
  62. Kaizu Y, Kimura M, Yoneyama T, et al.  Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis. 1998;31:93–100
  63. Kato A, Odamaki M, Takita T, et al.  Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int. 2002;62:945–955
  64. Moldawer LL, Andersson C, Gelin J, et al.  Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol. 1988;254:G450–G456

☆ Supported by NIDDK training grant 0711028.

PII: S1051-2276(03)00114-6

doi: 10.1016/S1051-2276(03)00114-6

Journal of Renal Nutrition
Volume 13, Issue 4 , Pages 250-258 , October 2003

Article Tools

* Image Usage & Resolution